NEW YORK (GenomeWeb) – The US Food and Drug Administration has accepted Myriad Genetics' supplementary premarket approval application for BRACAnalysis CDx as a test that may be used to identify metastatic breast cancer patients who are most likely to respond to AstraZeneca's Lynparza (olaparib).